Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 50Stomach Neoplasms 13Colonic Neoplasms 5Rectal Neoplasms 4Sarcoma 3Neoplasms 2Neoplasm Metastasis 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1TAS 102 1Sarcoma, Ewing 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1Locally Advanced Rectal Cancer 1HER2-positive Gastric Cancer 1Gastric Cancer Adenocarcinoma Metastatic 1Fruquintinib 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Colorectal Adenocarcinoma 1Carcinoma, Renal Cell 1

Interventions

Radiosurgery 79Capecitabine 77Oxaliplatin 74Fluorouracil 69Bevacizumab 69Gemcitabine 67Leucovorin 61pembrolizumab 53Nivolumab 53Paclitaxel 48Irinotecan 47Radiotherapy 45Cisplatin 44Everolimus 38Magnetic Resonance Spectroscopy 36Drug Therapy 36Docetaxel 36Cyclophosphamide 35Cetuximab 35Ipilimumab 32Carboplatin 32Trastuzumab 31Sunitinib 30Sorafenib 26Erlotinib Hydrochloride 25Doxorubicin 23Surveys and Questionnaires 20Surgical Procedures, Operative 20Specimen Handling 20Biopsy 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Neoplasm Metastasis × HMPL-013 × Clear all
NCT07042685 2026-04-09

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

The Methodist Hospital Research Institute

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT07446465 2026-03-03

FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer

Fudan University

Phase 4 Not yet recruiting
42 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡